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The large sums of money invested by drug companies in clinical 
research have resulted in a veritable research industry.  A great 
deal of this research is undertaken in the developing world, 
because these countries have a large burden of ‘treatment-naïve’ 
patients with chronic diseases who are willing to participate in 
human trials. However some of the regulations for research 
in developing countries are less stringent than in First-World 
countries. Furthermore the infrastructure to police such work 
is often lacking in the developing world.  Developing-world 
patients are often less informed about their rights and are less 
likely to have access to legal support in the event that they feel 
aggrieved. These unspoken issues have resulted in there being 
a negative perception about clinical drug trials among certain 
stakeholders in the developing world.  Another issue of concern 
has been political.  In many ways the situation in the world of 
knowledge reflects the situation as seen in that of trade, with 
the developing world being rich in natural resources but poor in 
infrastructure. Consequently the relationship is one of extraction. 
First-World researchers are perceived as moving in and strip-
mining the developing  world, without benefiting patients or 
acknowledging the contribution of local scientists. Managing 
research in the developing world is a delicate balancing act in 
which the rights of vulnerable communities need to be protected 
while facilitating valuable research that may provide meaningful 
knowledge and therapies.
Historical overview
Although human research has always been part of medicine, 
Nazi doctors created an outcry when their cruel and inhuman 
experiments became public knowledge.
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 In response the 
court at Nuremberg issued a 10-point declaration about 
human research that included the absolute need for voluntary 
consent, a tangible potential benefit, the avoidance of harm or 
suffering to the participants and the presence of trained and 
scientifically qualified individuals to supervise the experiment. 
In 1954 the World Medical Association (WMA) adopted a code 
for research and in 1964 published the Helsinki Declaration. 
These declarations and the growing concern for human rights 
resulted in legislation in many countries which mandated 
strategies designed to ensure ethical human research. Most 
of these strategies involved the creation of institutional review 
boards to oversee the ethics of clinical research. The thalidomide 
disaster prompted public concern and added impetus to the 
empowerment of statutory medicine control and regulatory 
bodies. Drugs could not be marketed without the approval 
of these bodies. The rise to prominence of the double-blind 
randomised controlled trial for the testing of new drugs prior  to 
regulatory body approval has meant that a great deal of pressure 
is placed on institutional ethics boards to make sure that research 
is approved expeditiously. Drug companies spend huge amounts 
of money on researching new therapeutic drugs. The potential 
profits are great. There is a direct conflict of interests in this as 
drug companies bring tremendous pressure to bear to get their 
trials approved, but the review boards need to remain true to their 
mandate which is to protect the participants in trials. This conflict 
may be particularly acute in developing-world settings.
Ethical research
Numerous academic and non-governmental bodies have 
attempted to provide guidelines for human research in the 
modern world. Good clinical practice guidelines are designed 
to enhance and foster human rights within clinical trials while 
ensuring that there is safety and efficacy in the proposed new 
therapy. There are several criteria which are generally regarded 
as ‘making  research ethical’.
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  The research must enhance 
health or knowledge and must be scientifically valid. Subject 
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selection must be fair and there must be a favourable risk-
benefit ratio. All research must be independently reviewed and 
informed consent is essential for all enrolled subjects. However, 
in research there remains a direct conflict between the pillars 
of modern medical ethics. The physician is asking a patient to 
take part in an experiment which may not directly benefit the 
individual concerned in the hope that a broader benefit may 
accrue to society as a whole.
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  Furthermore the double-blind 
randomised placebo control trial involves deception. If we enrol 
patients in a study we must be particularly vigilant to protect 
them and their interests. The institutional ethics review board 
has to protect the rights and look after the interests of research 
participants under the board’s jurisdiction. At the same time the 
boards do not want to become obstacles to meaningful research. 
This involves the risk-benefit ratio. Research is essential to 
generate new knowledge which may hold potential benefit for 
society. However, it is unacceptable that new knowledge is 
generated at the expense of the human subjects that participate 
in it. With the amount of money invested in research, particularly 




Doing research in the developing 
world
There are significant inequalities in the modern world and 
many people in the world today are particularly vulnerable to 
exploitation. Whether it is peasants selling kidneys, poor women 
working as prostitutes or children picking fruit, the relationships 
between people in the developed world and the developing 
world are not equal. Why should this interest the pharmaceutical 
companies?  The huge populations in the developing world 
mean that enrolling patients with a particular disease process is 
much easier than in the developed world. Furthermore there is 
a greater chance that these patients may actually be treatment-
naïve. This may allow for an improved power in the research 
design as there may be no pre-existing drugs that cloud the 
response to the new drug being tested. These are legitimate 
reasons for doing research in the developing world. However, 
there are other unmentioned features which may make doing 
research in the developing world more attractive for companies. 
One of these is the lack of governance in the developing 
world. Simply put, there are not enough trained and qualified 
officials to adequately supervise a clinical trial.  This means 
that there will be less regulation to control research and there 
will be fewer officials capable of enforcing whatever regulations 
are in place. It is in the nature of all corporations to drive out 
costs and maximise profits. If this is not accompanied by a firm 
commitment to ethical behaviour then this may well result in 
abuse. With regard to pharmaceutical companies in developing 
countries in particular, the lack of adequate governance and 
oversight of research means that ethics review boards are in a 
particularly difficult situation. On the one hand there are huge 
financial benefits that a region or institution can accrue by taking 
part in drug-company-sponsored research, but at the same time 
extremely vulnerable groups will be expected to participate in 
these trials.
The politics of research
Nothing exists in isolation and we cannot separate the creation 
of knowledge from the current system of commerce and politics 
that exists in the world today. A rich and powerful developed 
world coexists with a poor and disenfranchised developing world. 
Developing countries remain sources of raw natural resources 
and cheap labour while the developed countries remain as 
centres for production and manufacturing.  This situation of 
inequality is often replicated in clinical research. Researchers 
from well-funded and prestigious institutions will descend on a 
country, use its local people as research subjects, use its local 
scientists and administrative staff for support and extract the 
raw data. These raw data are then exported to the developed 
country for processing where it is turned into the finished product 
of a scientific publication or a higher degree. Often the country 
where the research was conducted receives little in return. The 
local scientists are not adequately acknowledged, and the funds 
and profits that result from the successful piece of research 
remain in the foreign institution. There are cases where First-
World researchers exploit local researchers as well, underpaying 
them for their work while frequently not even giving them part of 
the intellectual credit. Once approved for general use the high 
cost of new therapies may mean that trial participants and the 
indigent population of the developing country where the trial took 
place are denied future access to any new therapies. Ethics 
committees and review boards in the developing world need to 
be sensitive to these concerns. 
Money and scientific integrity
Huge amounts of money are involved in modern pharmaceutical 
research.
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 For this research to be credible it must be done in 
conjunction with trained and qualified scientists and doctors. 
This creates a conflict of interests. A doctor is supposed to be 
committed to the care of the patient and to the development 
of knowledge. A pharmaceutical company is however not 
dedicated to the creation of knowledge, but to the pursuit of 
profit. Over the last two decades there has been an increasing 
tendency for money to influence the outcome of scientific work. 
There are many ways in which research may be skewed and 
data manipulated.
6
 These would include direct falsification or 
fabrication of data, the deliberate faulty design of an experiment, 
trimming data and leaving out data which do not support a 
hypothesis.
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 Ethics committees need to be vigilant when it 
comes to these conflicts of interest. Almost all the major conflicts 
of interest that have arisen over the last 15 years have involved 
quite significant financial interests. The inherent inequalities in 
the developing world tend to exacerbate these potential conflicts 
of interest. 
The research agenda
Choosing a field of research is a conscious decision and, once 
made, it means that resources which could have been used 
to research another field will be diverted to this new field. It is 
however important for society, and hence for ethics committees, 
to help decide where their priorities are in deciding on research. 
The choice is seldom based on a simple utilitarian calculus of 
deciding which field of research will promote the most general 
happiness and well-being. This is because the major motivating 
factor behind a company choosing a disease of interest is in 
potential profits. Globally, infective diseases such as tuberculosis 
and malaria kill more people on a daily basis than any of the 
so-called diseases of affluence like cancer or cardiovascular 
disease. Yet very few drug companies are heavily involved 
in research about malaria or tuberculosis. It would seem that 
there is not much profit to be made in treating developing world 
infective diseases. Diseases that affect westerners are much 
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more likely to be the subject of major research. Once again 
ethics committees in the developing world must raise this as 
an issue. Their responsibility is to protect the subjects who will 
participate and to facilitate research while doing so, but they 
must be vocal on the issue of what is selected as a suitable 
topic for research. In some ways ethics boards in the developing 
world need to adopt an activist role in trying to ensure that the 
research agenda is not simply reflective of the existing power 
relationships in the modern world.
The current South African response
South Africa is a developing country and ethicists in South 
Africa need to be advocates rather than mere overseers of 
patient rights. In light of these concerns there has been a 
comprehensive legislative and policy response. In 2001 the 
National Department of Health (NDOH) published the Health 
Research Policy document.
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 The Policy provides enabling 
guidelines for health research in South Africa while protecting 
the interests of the most vulnerable groups in society. Within 
the NDOH, The National Directorate: Health Research is 
responsible for the co-ordination of research and has mandated 
the establishment of Provincial Health Research Committees 
(PHRCs). Each PHRC must oversee research at provincial 
level. The National Health Act of 2003
11
 provides a legislative 
framework for the establishment of a National Ethics Research 
Council (NERC). The Act states that the NERC must ensure 
that health research agendas and resources focus on priority 
health problems. These must be informed by the burden of 
disease, cost effectiveness of the proposed therapy and capacity 
to implement the interventions. The health needs of vulnerable 
groups and communities must be prioritised. At the end of 2005 
the NDOH issued a notice that all new clinical trials need to be 
registered in the South African National Clinical Trials Register.
12 
The National Health Research Ethics Council (NHREC) was 
established in October 2006.
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 This is a central body which 
advises the NDOH on research ethics and which oversees and 
accredits local ethics committees. The NHREC is tasked with 
setting norms, adjudicating disputes and instituting disciplinary 
measures where appropriate. In 2006 updated Good Clinical 
Practice Guidelines were published.
14
 However despite this 
strong and progressive policy and legislative response, lack of 
capacity may bedevil effective implementation. The NDOH has 
identified several barriers to the establishment and functioning 
of provincial ethics committees, which need to be addressed. 
These include financial constraints, lack of political will, lack of 
expertise and lack of human resources. 
Conclusion
Ethics committees and institutional review boards in South Africa 
have a number of important roles to play. They must ensure 
that the research being done in their jurisdiction is scientifically 
valid and respects the principles of Nuremberg and Helsinki. It is 
important to remember that the participants in the study are often 
doubly jeopardised by their poverty and by their disease process. 
As such the responsibilities of an ethics review board are much 
broader in the South African context than in the developed 
world. The board must keep in mind the social implications of 
the proposed research and seek always to prevent and reduce 
exploitative behaviour. South African ethics boards need to insist 
that funding and profits derived from research find their way back 
into the community in which the research was done. They need 
to be advocates for the most disadvantaged in the study, namely 
the participants. In South Africa ethics review boards need to 
play an activist role in human rights advocacy and the promotion 
of the interests of patients. Although there has been a strong 
legislative and policy response to these issues in South Africa, 
resource limitations may serve to hinder implementation.
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